120 related articles for article (PubMed ID: 33476198)
1. Can circulating miR-7-1-5p, and miR-33a-5p be used as markers of T2D patients?
Saeidi L; Shahrokhi SZ; Sadatamini M; Jafarzadeh M; Kazerouni F
Arch Physiol Biochem; 2023 Jun; 129(3):771-777. PubMed ID: 33476198
[TBL] [Abstract][Full Text] [Related]
2. Can miR-145-5p be used as a marker in diabetic patients?
Shahrokhi SZ; Saeidi L; Sadatamini M; Jafarzadeh M; Rahimipour A; Kazerouni F
Arch Physiol Biochem; 2022 Oct; 128(5):1175-1180. PubMed ID: 32412315
[TBL] [Abstract][Full Text] [Related]
3. Circulating miR-148b-3p and miR-27a-3p can be potential biomarkers for diagnosis of pre-diabetes and type 2 diabetes: integrating experimental and in-silico approaches.
Ghoreishi E; Shahrokhi SZ; Kazerouni F; Rahimipour A
BMC Endocr Disord; 2022 Aug; 22(1):207. PubMed ID: 35978298
[TBL] [Abstract][Full Text] [Related]
4. Circulating serum microRNAs including senescent miR-31-5p are associated with incident fragility fractures in older postmenopausal women with type 2 diabetes mellitus.
Heilmeier U; Hackl M; Schroeder F; Torabi S; Kapoor P; Vierlinger K; Eiriksdottir G; Gudmundsson EF; Harris TB; Gudnason V; Link TM; Grillari J; Schwartz AV
Bone; 2022 May; 158():116308. PubMed ID: 35066213
[TBL] [Abstract][Full Text] [Related]
5. Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization.
Ortega FJ; Mercader JM; Moreno-Navarrete JM; Rovira O; Guerra E; Esteve E; Xifra G; Martínez C; Ricart W; Rieusset J; Rome S; Karczewska-Kupczewska M; Straczkowski M; Fernández-Real JM
Diabetes Care; 2014; 37(5):1375-83. PubMed ID: 24478399
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-33a-5p sponges to inhibit pancreatic β-cell function in gestational diabetes mellitus LncRNA DANCR.
Feng Y; Qu X; Chen Y; Feng Q; Zhang Y; Hu J; Li X
Reprod Biol Endocrinol; 2020 Jun; 18(1):61. PubMed ID: 32505219
[TBL] [Abstract][Full Text] [Related]
7. Circulating microRNAs as clinically useful biomarkers for Type 2 Diabetes Mellitus: miRNomics from bench to bedside.
Grieco GE; Besharat ZM; Licata G; Fignani D; Brusco N; Nigi L; Formichi C; Po A; Sabato C; Dardano A; Natali A; Dotta F; Sebastiani G; Ferretti E
Transl Res; 2022 Sep; 247():137-157. PubMed ID: 35351622
[TBL] [Abstract][Full Text] [Related]
8. A two-miRNA signature (miR-33a-5p and miR-128-3p) in whole blood as potential biomarker for early diagnosis of lung cancer.
Pan J; Zhou C; Zhao X; He J; Tian H; Shen W; Han Y; Chen J; Fang S; Meng X; Jin X; Gong Z
Sci Rep; 2018 Nov; 8(1):16699. PubMed ID: 30420640
[TBL] [Abstract][Full Text] [Related]
9. Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists.
Garabet L; Ghanima W; Rangberg A; Teruel-Montoya R; Martinez C; Lozano ML; Nystrand CF; Bussel JB; Sandset PM; Jonassen CM
Platelets; 2020; 31(2):198-205. PubMed ID: 30885035
[TBL] [Abstract][Full Text] [Related]
10. Blood-based analysis of 84 microRNAs identifies molecules deregulated in individuals with type-2 diabetes, risk factors for the disease or metabolic syndrome.
Avgeris M; Kokkinopoulou I; Maratou E; Mitrou P; Boutati E; Scorilas A; Fragoulis EG; Christodoulou MI
Diabetes Res Clin Pract; 2020 Jun; 164():108187. PubMed ID: 32360711
[TBL] [Abstract][Full Text] [Related]
11. CircRNA circ-ITCH improves renal inflammation and fibrosis in streptozotocin-induced diabetic mice by regulating the miR-33a-5p/SIRT6 axis.
Liu J; Duan P; Xu C; Xu D; Liu Y; Jiang J
Inflamm Res; 2021 Jul; 70(7):835-846. PubMed ID: 34216220
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness of plasma miR-33a-5p as a predictive biomarker for the efficacy of colorectal cancer chemotherapy.
Sasaki M; Ishikawa T; Ishiguro M; Okazaki S; Yamauchi S; Kikuchi A; Matsuyama T; Kawada K; Tokunaga M; Uetake H; Kinugasa Y
Oncol Lett; 2021 Jun; 21(6):489. PubMed ID: 33968205
[TBL] [Abstract][Full Text] [Related]
13. Decreased expression of microRNAs targeting type-2 diabetes susceptibility genes in peripheral blood of patients and predisposed individuals.
Kokkinopoulou I; Maratou E; Mitrou P; Boutati E; Sideris DC; Fragoulis EG; Christodoulou MI
Endocrine; 2019 Nov; 66(2):226-239. PubMed ID: 31559537
[TBL] [Abstract][Full Text] [Related]
14. A plasma circulating miRNAs profile predicts type 2 diabetes mellitus and prediabetes: from the CORDIOPREV study.
Jiménez-Lucena R; Camargo A; Alcalá-Diaz JF; Romero-Baldonado C; Luque RM; van Ommen B; Delgado-Lista J; Ordovás JM; Pérez-Martínez P; Rangel-Zúñiga OA; López-Miranda J
Exp Mol Med; 2018 Dec; 50(12):1-12. PubMed ID: 30598522
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-33a-5p suppresses growth of osteosarcoma cells and is downregulated in human osteosarcoma.
Zhang J; Wang D; Xiong J; Chen L; Huang J
Oncol Lett; 2015 Oct; 10(4):2135-2141. PubMed ID: 26622808
[TBL] [Abstract][Full Text] [Related]
16. B-RCA revealed circulating miR-33a/b associates with serum cholesterol in type 2 diabetes patients at high risk of ASCVD.
Deng X; Qin S; Chen Y; Liu HY; Yuan E; Deng H; Liu SM
Diabetes Res Clin Pract; 2018 Jun; 140():191-199. PubMed ID: 29601916
[TBL] [Abstract][Full Text] [Related]
17. Expression Profiles of Circulating microRNAs in South African Type 2 Diabetic Individuals on Treatment.
Weale CJ; Matshazi DM; Davids SFG; Raghubeer S; Erasmus RT; Kengne AP; Davison GM; Matsha TE
Front Genet; 2021; 12():702410. PubMed ID: 34567065
[No Abstract] [Full Text] [Related]
18. MicroRNA-33a-5p Modulates Japanese Encephalitis Virus Replication by Targeting Eukaryotic Translation Elongation Factor 1A1.
Chen Z; Ye J; Ashraf U; Li Y; Wei S; Wan S; Zohaib A; Song Y; Chen H; Cao S
J Virol; 2016 Jan; 90(7):3722-34. PubMed ID: 26819305
[TBL] [Abstract][Full Text] [Related]
19. CircRNA hsa_circ_0071336 is associated with type 2 diabetes through targeting the miR-93-5p/GLUT4 axis.
Yan YX; Dong J; Li YL; Lu YK; Yang K; Wang T; Zhang X; Xiao HB
FASEB J; 2022 May; 36(5):e22324. PubMed ID: 35439323
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-33a-5p suppresses esophageal squamous cell carcinoma progression via regulation of lncRNA DANCR and ZEB1.
Zhang C; Wang L; Yang J; Fu Y; Li H; Xie L; Cui Y
Eur J Pharmacol; 2019 Oct; 861():172590. PubMed ID: 31401160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
